Tanguler Tolga, EVP and Chief Commercial Officer at Alnylam Pharmaceuticals (ALNY), has demonstrated a consistent pattern of selling activity based on SEC Form 4 filings. Over 70 reported transactions, Tolga has exclusively sold shares, with no recorded purchases, totaling over $5.2 million in proceeds. The selling activity has been particularly concentrated in early 2026, with 21 separate sales executed between January and March. The largest single transaction occurred on February 13, 2026, when Tolga sold shares worth $607,448.29. March 2026 saw a flurry of mid-sized sales, including multiple transactions on March 2 and March 4 ranging from $12,307.68 to $248,385.28 in value.
Tolga’s trading history is exclusively tied to Alnylam, with no reported transactions in other companies. The recent sales, including those on March 4 totaling over $600,000 across eight separate filings, suggest an ongoing divestment strategy. While some transactions were relatively small—such as the January 12, 2026, sales of $5,242.16 and $5,667.30—the overall trend points to a steady reduction in holdings. The absence of any buy transactions, combined with the frequency and scale of recent sales, indicates a clear directional bias toward liquidation rather than accumulation of ALNY shares. The filings do not specify whether the sales were part of prearranged trading plans, but the pattern remains unambiguous in its sell-side orientation.
AI-assisted summary